REGN monthly performance report
Monthly REGN research: returns, drawdown, relative strength, seasonality, and key stats.
REGN monthly report
—
Key takeaways
- Regeneron Pharmaceuticals (REGN) closed August 2026 at $768.58, up 0.78% for the month and +34.86% over the trailing 12 months.
- Year-to-date, REGN is −0.43%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +7.76% versus its 200-day moving average ($713.25), a bullish technical signal.
- Over the past three years, REGN has underperformed the S&P 500 by −72.01%, with a relative strength index reading of 58.1.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 19 negative months.
Regeneron Pharmaceuticals ended August 2026 at $768.58, posting a monthly return of +0.78%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −2.27%.
The current quarter stands at +23.53% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +7.76% versus the 200-day moving average ($713.25).
Year-to-date, REGN is −0.43% against SPY +12.89%, a gap of −13.31%. The stock is currently −6.40% below its 52-week high, with maximum 3-year drawdown at −59.80%.
| Period | REGN | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +1.04% | −0.20% | +1.24% |
| 1 Week | +10.56% | +3.90% | +6.65% |
| 1 Month | +0.78% | +3.05% | −2.27% |
| 3 Months | +8.70% | +7.11% | +1.59% |